NEW YORK, June 30, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that Dr. Andrew Vaillant, Chief Scientific Officer, presented updated clinical data from the REP 301 clinical trial to the Global Virus Hepatitis Summit (15th International Symposium on Viral Hepatitis and Liver Disease) in Berlin Germany. This important conference focusing on the treatment of viral hepatitis occurs every three years.
Updated data included new safety and efficacy data in patients completing the combination therapy (REP 2139-Ca and Pegasys®) phase of the trial subsequent to the completion of REP 2139-Ca monotherapy (previously presented at the EASL ILC conference in Vienna on April 24, 2015). These data demonstrate the continued elimination of serum HDV RNA during combination treatment in all patients. The presentation can be viewed on the company’s website at: https://replicor.com/science/conference-presentations/.
The data from three previous Asian clinical trials, together with the evolving data from the current Caucasian REP 301 trial, demonstrate that REP 2139 used alone or in combination with Pegasys®, ZADAXIN® or Pegasys® and ETV) continues to be safe and well-tolerated. With REP 2139-Ca used as a backbone therapy in combination with various immunotherapies and ETV, antiviral responses continue to be profound, documenting up to 7 log reduction and clearance of surface antigen, 6 log reduction and clearance of serum HBV DNA and or HDV RNA and, a significantly increases the 12-month SVR rate in patients with chronic HBV infection compared to existing therapies.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.